Allergic asthma is associated with T helper (Th) 2 cell‐biased immune responses and characterized by the airway hyperresponsiveness (AHR). Studies have shown that the acupoint catgut‐embedding therapy (ACE) has a therapeutic effect on allergic asthma. However, the relevant mechanism is poorly understood. In present study, female BALB/c mice were sensitized and challenged with ovalbumin (OVA) to establish a model of allergic asthma. AHR was evaluated by using airway resistance (R_L) and lung dynamic compliance (Cdyn). Airway inflammation and mucus hypersecretion were observed by HE and PAS staining. Inflammatory cells were counted, and related cytokines in bronchoalveolar lavage fluid (BALF) were detected by enzyme‐linked immunosorbent assay (ELISA). Pulmonary group 2 innate lymphoid cell (ILC2s) proportions were analyzed by flow cytometry. The expression of nuclear factor κB (NF‐κB) and cyclooxygenase‐2 (COX‐2) was detected by immunostaining. Our results showed that OVA induction resulted in a significant increase in R_L, accompanied by a significant decrease in Cdyn. The levels of interleukin‐ (IL‐) 4, IL‐13, OVA‐specific IgE in BALF, and the percentage of ILC2 in the lungs were markedly increased accompanied by a significant decreased in interferon‐γ (IFN‐γ). Furthermore, the expressions of p‐NF‐κB p65 and COX‐2 in airways were significantly upregulated. After ACE treatment, the indicators above were significantly reversed. In conclusion, ACE treatment inhibited the secretion of Th2 cytokines and the proliferation of ILC2s in the lungs, thereby dampening the inflammatory activity in allergic asthma. The underlying mechanism might be related to the inhibition of NF‐κB/COX‐2 pathway.

Introduction: The incidence of insomnia is getting higher and higher. Long-term insomnia seriously affects people’s health. Drug use is usually accompanied with adverse events. Both acupuncture and cognitive behavioral therapy for insomnia (CBT-I) have been proven to be safe and effective non-pharmacological treatments for insomnia. As the insomniacs’ bad sleep behavior and wrong cognition have not been effectively corrected, acupuncture has a quick effect, high patient compliance but unstable long-term efficacy, while CBT-I is complex, time-consuming, and expensive; additionally, patient compliance is low, and the number of trained therapists is limited, making it difficult to carry out. Therefore, this study aims to use the insomnia TCM system to construct a convenient and feasible traditional Chinese medicine e-aid cognitive behavioral therapy for insomnia (TCM-eCBT-I) for Chinese people, and combine the advantages of acupuncture and TCM-eCBT-I for maintaining long-term efficacy, and three treatments will be evaluated to provide clinicians with a more effective clinical protocol Methods and analysis: This study is a single-center, open-label, randomized controlled trial. Ninety subjects will be recruited and randomly assigned to three groups: the acupuncture group, the TCM-eCBT-I group, and the acupuncture combined with TCM-eCBT-I group, in a ratio of 1:1:1. We will evaluate the Pittsburgh Sleep Quality Index (PSQI) and Dysfunctional Beliefs and Attitudes About Sleep Scale (DBAS), Insomnia Severity Index (ISI), sleep diary, Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Fatigue Scale-14 Scale (FS-14) scales. All adverse reactions will be assessed through the ADVERSE event table. All outcomes will be evaluated online at 0 weeks, 4 weeks, 8 weeks, 16 weeks, and 28weeks. Ethics and dissemination: This study has been approved by the Institutional Review Board of the Affiliated Hospital of Nanjing University of Chinese Medicine (2020 NL-018-02). Informed consent will be obtained from all the subjects. The results will be shared with sleep researchers, public, and relevant academic institutions through high-impact peer-reviewed publications. Trial registration: Chinese Clinical Trial Registry ChiCTR2000032960. Registered on 17 May 2020

Background: The interactions and associations between obstructive sleep apnea (OSA), sleep-related phenotypes (SRPs), and gastroesophageal reflux disease (GERD) are complex, thus it is hard to explore the effect and direction of causalities.Study objectives: A bidirectional Mendelian randomization (MR) study was performed to explore causal associations of GERD with OSA and SRPs (including insomnia, morningness, sleep duration, ease of getting up, daytime napping, daytime dozing, and snoring).Methods: First, we gathered summary statistics from publicly available databases. Subsequently, we identified single-nucleotide polymorphisms without strong linkage (r² ≤ 0.001) by referencing relevant genome-wide association studies that met genome-wide significance criteria. Our primary analysis relied on inverse variance weighted to estimate the causal relationship. To ensure the validity of our findings, we also conducted several sensitivity analyses. These included MR Pleiotropy RESidual Sum and Outlier to detect and correct for potential pleiotropic effects, MR-Egger to assess directional pleiotropy, and weighted median analysis to further evaluate heterogeneity and pleiotropy. For the initial MR analysis, when causality was indicated by the results, instrumental variables that were significantly linked to the aforementioned confounding factors were removed. We will re-analyze the data after excluding outcome-related single nucleotide polymorphisms to confirm that the results are still consistent with the previous results.Results: GERD was found to increase the risk of OSA (OR = 1.53, 95% CI = 1.37–1.70, p = 5.3 × 10⁻¹⁵), insomnia (OR = 1.14, 95% CI = 1.10–1.19, p = 1.3 × 10⁻¹⁰), snoring (OR = 1.09, 95% CI = 1.04–1.13, p = 6.3 × 10⁻⁵) and less sleep duration (OR = 0.94, 95% CI = 0.91–0.97, p = 3.7 × 10⁻⁴). According to the reverse-direction analysis, there is an elevated risk of GERD associated with OSA (OR = 1.07, 95% CI = 1.02–1.12, p = 0.005), insomnia (OR = 1.95, 95% CI = 1.60–2.37, p = 1.92 × 10⁻¹¹) and snoring (OR = 1.74, 95% CI = 1.37–2.21, p = 4.4 × 10⁻⁶).Conclusion: Genetic susceptibility to GERD can elevate the likelihood of experiencing insomnia, snoring, and OSA, in addition to diminishing sleep duration. Conversely, a reverse MR analysis indicates that ameliorating any one of insomnia, snoring, or OSA can mitigate the risk of developing GERD.

Purpose. The purpose of this study is to determine the mechanism of improvement in dry eye diseases (DEDs) treated by acupuncture. The inflammatory molecules and related pathways will be analyzed in our study. Methods. In order to establish the animal model for DEDs, healthy New Zealand white rabbits were treated with scopolamine (Scop) hydrobromide for 21 consecutive days. After 21 days, acupuncture, fluorometholone (Flu), and α7nAChR antagonist (α-BGT) treatments were performed, and the Scop injections were continued until day 35. The therapeutic effect of acupuncture on DED inflammation was evaluated by corneal fluorescence staining, tear film rupture time, tear flow measurement, in vivo confocal microscopy (IVCM), corneal histopathology, and cytokine protein chip technology. The influence of acupuncture on the corneal pathology and inflammatory factors ACh, α7nAChR, and NF-κB was detected by enzyme-linked immunosorbent assay (ELISA) and western blot. Results. Compared with the group Scop, acupuncture can significantly reduce corneal staining and increase the tear film rupture time and tear flow, which are accompanied by a decrease in corneal epithelial detachment and lymphocyte infiltration. Acupuncture can relieve the inflammation of corneal stroma and mitigate the expression of proinflammatory factors and chemokines. Acupuncture can upregulate the expression of ACh and α7nAChR and downregulate the expression of NF-κB. Conclusion. Our findings demonstrate that acupuncture can alleviate corneal inflammation in New Zealand white rabbits with DEDs via α7nAChR and NF-κB signaling pathway regulation. The expression indicates that α7nAChR/NF-κB signaling pathway may be active and that acupuncture is a potential therapeutic target for dry eye.

Background: Insomnia is the most prevalent sleep disorder worldwide. Electroacupuncture is effective in improving sleep quality, daytime fatigue status, and anxiety and depression in patients with insomnia, and this study aimed to investigate the metabolic pathways and their possible mechanisms in response to the efficacy of electroacupuncture in the treatment of insomnia.Methods: A single-center, double-blind, clinical trial was the study’s design. For this study, a total of 99 participants were enrolled, and they will be split into two groups: one for insomnia and the other for health. There are 33 healthy people in the healthy group and 66 insomnia patients in the insomnia group. Acupuncture treatment will be administered to the intervention group three times a week for four weeks, for a total of twelve treatments, and will be followed up for 3 months. A combination of UPLC-Q/TOF-MS and UPLC-QQQ-MS/MS was used to qualitatively and quantitatively examine the serum of 99 participants. The Pittsburgh Sleep Quality Index (PSQI) and serum metabolomics provided the primary findings. The Insomnia Severity Index (ISI), Hyperarousal Scale (HAS), Fatigue Feverity Scale (FSS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Sleep Diary and The Montreal Cognitive Assessment (MoCA) were the secondary outcomes. For the insomnia group, serum will be collected at baseline, at the end of treatment, and the scale will be collected at baseline, after 4 weeks of treatment, and at 3 months of follow-up. For the healthy group, serum will be collected at baseline.Discussion: This study aimed to assess the modulatory effects of electroacupuncture on relevant metabolic markers using serum metabolomics, to explore the potential mechanisms and relevant metabolic pathways of electroacupuncture for the treatment of insomnia, and to provide strong scientific evidence for the treatment of insomnia by electroacupuncture.Trial registration: ChiCTR2400085660 (China Clinical Trial Registry, http://www.chictr.org.cn, registered on June 14, 2024)